Research Group: Structural Biochemistry

Chimeric antigen receptor (CAR) T-cell therapy is based on engineered immune cells that find and destroy cancer cells. However, sometimes these cells also attack healthy tissues, causing side effects. An international team of researchers, including LIT scientists Dr. Leo Scheller, Dr. Markus Barden, and Prof. Hinrich Abken, has now developed a system to control T-cell binding to other cells by an approved small molecule drug.